Business Today

AbCellera and IGM Biosciences collaborates to develop antibodies (NASDAQ:IGMS)

AbCellera and IGM Biosciences (NASDAQ:IGMS) entered right into a multi-year, multi-target strategic analysis collaboration and license agreement to facilitate the invention and growth of novel IgM antibodies.

AbCellera will generate panels of antibodies for a number of therapeutic targets recognized by IGM utilizing its full-stack, AI-powered antibody discovery know-how.

Monetary phrases of the collaboration weren’t disclosed.

“Engineered IgM and IgA antibodies could possibly overcome among the limitations of the present IgG-based therapeutics, and this partnership demonstrates the depth of our dedication to making sure that the potential of our IgM and IgA know-how platform is absolutely realized in areas of excessive unmet medical want.” mentioned Fred Schwarzer, CEO of IGM Biosciences.

Leave a Reply

Your email address will not be published. Required fields are marked *